Abstract
Summary
Europe Artificial Intelligence (AI) in drug discovery market is projected to register a substantial CAGR of 52.0% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2022 to 2029.
Market Segmentation
Europe Artificial Intelligence (AI) in Drug Discovery Market, By Application (Novel Drug Candidates, Drug Optimization and Repurposing Preclinical Testing and Approval, Drug Monitoring, Finding New Diseases Associated Targets and Pathways, Understanding Disease Mechanisms, Aggregating and Synthesizing Information, Formation & Qualification of Hypotheses, De Novo Drug Design, Finding Drug Targets of an Old Drug, and Others), Technology (Machine Learning, Deep Learning, Natural Language Processing, and Others), Drug Type (Small Molecule and Large Molecule), Offering (Software and Services.), Indication (Immuno-Oncology, Neurodegenerative Diseases, Cardiovascular Diseases, Metabolic Diseases, and Others), End Use (Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the Europe Artificial Intelligence (AI) in drug discovery market are:
• Rise in incidence of chronic diseases propels need for AI in drug discovery
• Strategic collaborations, partnerships and products launch
Market Players
The key market players operating in the Europe Artificial Intelligence (AI) in drug discovery market are listed below:
• NVIDIA Corporation
• IBM Corp.
• Atomwise Inc.
• Microsoft
• Envisagenics
• Owkin Inc.
• BERG LLC
• Schrödinger, Inc.
• XtalPi Inc.
• BIOAGE Inc.
Table of Contents
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF EUROPE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET 33
1.4 CURRENCY AND PRICING 35
1.5 LIMITATIONS 35
1.6 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
2.1 MARKETS COVERED 39
2.2 GEOGRAPHICAL SCOPE 40
2.3 YEARS CONSIDERED FOR THE STUDY 41
2.4 DBMR TRIPOD DATA VALIDATION MODEL 42
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.6 MULTIVARIATE MODELLING 46
2.7 MARKET APPLICATION COVERAGE GRID 47
2.8 SOURCE LIFELINE CURVE 48
2.9 DBMR MARKET POSITION GRID 49
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHT 57
4.1 PESTEL ANALYSIS 58
4.2 PORETSR’S FIVE FORCES 59
5 MARKET OVERVIEW 60
5.1 DRIVERS 62
5.1.1 THE RISE IN INCIDENCE OF CHRONIC DISEASES PROPELS NEED FOR ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY 62
5.1.2 STRATEGIC COLLABORATIONS, PARTNERSHIPS, AND PRODUCTS LAUNCH 62
5.1.3 REDUCTION IN TOTAL TIME INVOLVED IN DRUG DISCOVERY PROCESS 63
5.1.4 ADVANCEMENT OF ARTIFICIAL INTELLIGENCE IN THE HEALTHCARE INDUSTRY 63
5.2 RESTRAINTS 64
5.2.1 HIGH COST ASSOCIATED WITH TECHNOLOGY AND TECHNICAL LIMITATIONS 64
5.2.2 DISADVANTAGES AND RISKS ASSOCIATED WITH AI IN DRUG DISCOVERY 64
5.2.3 LACK OF AVAILABLE QUALITY DATA 64
5.3 OPPORTUNITIES 65
5.3.1 RISE IN THE INVESTMENTS FOR R&D 65
5.3.2 RISING HEALTHCARE INFRASTRUCTURE 65
5.3.3 DEVELOPMENT OF NOVEL TOOLS 66
5.4 CHALLENGES 66
5.4.1 THE EUROPE SHORTAGE OF AI TALENT 66
5.4.2 ETHICAL, LEGAL, AND REGULATORY ISSUES FOR AI ADOPTION IN THE PHARMACEUTICAL SCIENCES 67
6 EUROPE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY OFFERING 68
6.1 OVERVIEW 69
6.2 SOFTWARE 72
6.2.1 INTEGRATED 73
6.2.2 STANDALONE 73
6.3 SERVICES 73
7 EUROPE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 75
7.1 OVERVIEW 76
7.2 MACHINE LEARNING (ML) 79
7.2.1 SUPERVISED LEARNING 80
7.2.2 UNSUPERVISED LEARNING 80
7.2.3 REINFORCEMENT LEARNING 80
7.3 DEEP LEARNING 80
7.4 NATURAL LANGUAGE PROCESSING (NLP) 81
7.5 OTHERS 82
8 EUROPE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY DRUG TYPE 83
8.1 OVERVIEW 84
8.2 SMALL MOLECULE 87
8.3 LARGE MOLECULE 87
9 EUROPE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY APPLICATION 89
9.1 OVERVIEW 90
9.2 NOVEL DRUG CANDIDATES 93
9.2.1 PREDICT BIOACTIVITY OF SMALL MOLECULE 94
9.2.2 IDENTIFY BIOLOGICS TARGET 94
9.2.3 OTHERS 94
9.3 DRUG OPTIMISATION AND RE-PURPOSING PRE-CLINICAL TESTING AND APPROVAL 94
9.4 DRUG MONITORING 95
9.5 AGGREGATING AND SYNTHESIZING INFORMATION 96
9.6 DE NOVO DRUG DESIGN 96
9.7 FINDING DRUG TARGETS OF AN OLD DRUG 97
9.8 FORMATION & QUALIFICATION OF HYPOTHESES 98
9.9 UNDERSTANDING DISEASE MECHANISMS 99
9.10 FINDING NEW DISEASE-ASSOCIATED TARGETS AND PATHWAYS 99
9.11 OTHERS 100
10 EUROPE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY INDICATION 102
10.1 OVERVIEW 103
10.2 IMMUNE-ONCOLOGY 106
10.2.1 BREAST CANCER 107
10.2.2 LUNG CANCER 107
10.2.3 COLORECTAL CANCER 107
10.2.4 PROSTATE CANCER 107
10.2.5 PANCREATIC CANCER 107
10.2.6 BRAIN CANCER 107
10.2.7 LEUKEMIA 108
10.2.8 OTHERS 108
10.3 NEURODEGENERATIVE DISEASES 108
10.4 CARDIOVASCULAR DISEASES 109
10.5 METABOLIC DISEASES 109
10.6 OTHERS 110
11 EUROPE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET , BY END USE 111
11.1 OVERVIEW 112
11.2 CONTRACT RESEARCH ORGANIZATIONS 115
11.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 115
11.4 RESEARCH CENTERS AND ACADEMIC INSTITUTES 116
11.5 OTHERS 117
12 EUROPE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET, BY REGION 118
12.1 EUROPE 119
12.1.1 U.K. 127
12.1.2 FRANCE 131
12.1.3 GERMANY 135
12.1.4 SPAIN 139
12.1.5 ITALY 143
12.1.6 RUSSIA 147
12.1.7 NETHERLANDS 151
12.1.8 SWITZERLAND 155
12.1.9 TURKEY 159
12.1.10 BELGIUM 163
12.1.11 REST OF EUROPE 167
13 EUROPE ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY MARKET: COMPANY LANDSCAPE 168
13.1 COMPANY SHARE ANALYSIS: EUROPE 168
14 SWOT ANALYSIS 169
15 COMPANY PROFILES 170
15.1 NVIDIA CORPORATION 170
15.1.1 COMPANY SNAPSHOT 170
15.1.2 REVENUE ANALYSIS 170
15.1.3 COMPANY SHARE ANALYSIS 171
15.1.4 PRODUCT PORTFOLIO 171
15.1.5 RECENT DEVELOPMENTS 171
15.2 MICROSOFT 172
15.2.1 COMPANY SNAPSHOT 172
15.2.2 REVENUE ANALYSIS 172
15.2.3 COMPANY SHARE ANALYSIS 173
15.2.4 PRODUCT PORTFOLIO 173
15.2.5 RECENT DEVELOPMENT 173
15.3 IBM CORP 174
15.3.1 COMPANY SNAPSHOT 174
15.3.2 REVENUE ANALYSIS 174
15.3.3 COMPANY SHARE ANALYSIS 175
15.3.4 PRODUCT PORTFOLIO 175
15.3.5 RECENT DEVELOPMENT 175
15.4 SCHRÖDINGER, INC. 176
15.4.1 COMPANY SNAPSHOT 176
15.4.2 REVENUE ANALYSIS 176
15.4.3 COMPANY SHARE ANALYSIS 177
15.4.4 PRODUCT PORTFOLIO 177
15.4.5 RECENT DEVELOPMENTS 177
15.5 BERG LLC 179
15.5.1 COMPANY SNAPSHOT 179
15.5.2 COMPANY SHARE ANALYSIS 179
15.5.3 PRODUCT PORTFOLIO 179
15.5.4 RECENT DEVELOPMENTS 180
15.6 ARDIGEN 181
15.6.1 COMPANY SNAPSHOT 181
15.6.2 PRODUCT PORTFOLIO 181
15.6.3 RECENT DEVELOPMENTS 181
15.7 EXSCIENTIA 182
15.7.1 COMPANY SNAPSHOT 182
15.7.2 REVENUE ANALYSIS 182
15.7.3 PRODUCT PORTFOLIO 183
15.7.4 RECENT DEVELOPMENTS 183
15.8 ARIA PHARMACEUTICALS, INC. 184
15.8.1 COMPANY SNAPSHOT 184
15.8.2 PRODUCT PORTFOLIO 184
15.8.3 RECENT DEVELOPMENTS 184
15.9 ATOMWISE INC. 186
15.9.1 COMPANY SNAPSHOT 186
15.9.2 PRODUCT PORTFOLIO 186
15.9.3 RECENT DEVELOPMENTS 186
15.10 BENEVOLENT AI 188
15.10.1 COMPANY SNAPSHOT 188
15.10.2 REVENUE ANALYSIS 188
15.10.3 PRODUCT PORTFOLIO 189
15.10.4 RECENT DEVELOPMENTS 189
15.11 BIOAGE INC., 190 15.11.1 COMPANY SNAPSHOT 190
15.11.2 PRODUCT PORTFOLIO 190
15.11.3 RECENT DEVELOPMENTS 190
15.12 CLOUD 191
15.12.1 COMPANY SNAPSHOT 191
15.12.2 PRODUCT PORTFOLIO 191
15.12.3 RECENT DEVELOPMENT 191
15.13 CYCLICA 192
15.13.1 COMPANY SNAPSHOT 192
15.13.2 PRODUCT PORTFOLIO 192
15.13.3 RECENT DEVELOPMENTS 192
15.14 DEEP GENOMICS 194
15.14.1 COMPANY SNAPSHOT 194
15.14.2 PRODUCT PORTFOLIO 194
15.14.3 RECENT DEVELOPMENTS 194
15.15 ENVISAGENICS 196
15.15.1 COMPANY SNAPSHOT 196
15.15.2 PRODUCT PORTFOLIO 196
15.15.3 RECENT DEVELOPMENTS 196
15.16 INSILICO MEDICINE 198
15.16.1 COMPANY SNAPSHOT 198
15.16.2 PRODUCT PORTFOLIO 198
15.16.3 RECENT DEVELOPMENTS 198
15.17 NUMEDII, INC. 200
15.17.1 COMPANY SNAPSHOT 200
15.17.2 PRODUCT PORTFOLIO 200
15.17.3 RECENT DEVELOPMENT 200
15.18 OWKIN INC. 201
15.18.1 COMPANY SNAPSHOT 201
15.18.2 PRODUCT PORTFOLIO 201
15.18.3 RECENT DEVELOPMENT 201
15.19 XTALPI INC. 202
15.19.1 COMPANY SNAPSHOT 202
15.19.2 PRODUCT PORTFOLIO 202
15.19.3 RECENT DEVELOPMENTS 202
16 QUESTIONNAIRE 204
17 RELATED REPORTS 207